Dr. Alice Long received her BS degree in Biology from Macalester College in St. Paul, MN, and earned her PhD in Immunology from Emory University in Atlanta, GA. She then pursued post-doctoral studies at the University of California at Davis studying the etiology and pathogenesis of primary biliary cirrhosis, an autoimmune disease of the liver. She next joined a Seattle-based biotechnology company, Xcyte Therapies, where she helped develop adoptive T-cell therapies for multiple diseases. In 2005, she joined Benaroya Research Institute (BRI) as a staff scientist. In 2011, she joined the faculty at BRI and is currently an Associate Member and Manager of the Human Immunophenotyping Core.

Dr. Long’s lab is a translational immunology lab focused on using human samples to understand etiology, pathogenesis, disease heterogeneity and treatment response. Specifically, her current research includes three inter-related projects: 1) causes and consequences of reduced IL-2 signaling in T1D subjects, 2) cellular definition, function and stability of CD8 exhaustion associated with beneficial response to therapy, and 3) identification of biomarkers of disease progression.